PDSB

PDS Biotechnology Corp

PDSB, USA

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

https://www.pdsbiotech.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PDSB
stock
PDSB

PDS Biotechnology (PDSB) upgraded to buy: Here's why MSN

Read more →
PDSB
stock
PDSB

Stocks of PDS Biotechnology Corporation (PDSB) are poised to climb above their peers Setenews

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7.5

Analyst Picks

Strong Buy

2

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.88

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-95.30 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-25.96 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

2.67

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 20.64% of the total shares of PDS Biotechnology Corp

1.

Armistice Capital, LLC

(4.7549%)

since

2025/06/30

2.

Vanguard Group Inc

(4.1495%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(2.1168%)

since

2025/07/31

4.

Vanguard Institutional Extnd Mkt Idx Tr

(1.2799%)

since

2025/07/31

5.

UBS Group AG

(1.1547%)

since

2025/06/30

6.

BlackRock Inc

(1.0939%)

since

2025/06/30

7.

Geode Capital Management, LLC

(0.8887%)

since

2025/06/30

8.

Fidelity Extended Market Index

(0.5375%)

since

2025/07/31

9.

Blair William & Co

(0.5316%)

since

2025/06/30

10.

Citadel Advisors Llc

(0.5296%)

since

2025/06/30

11.

State Street Corp

(0.2835%)

since

2025/06/30

12.

Northern Trust Corp

(0.2599%)

since

2025/06/30

13.

Renaissance Technologies Corp

(0.2247%)

since

2025/06/30

14.

iShares Micro-Cap ETF

(0.2113%)

since

2025/08/31

15.

Squarepoint Ops LLC

(0.2079%)

since

2025/06/30

16.

Commonwealth Equity Services Inc

(0.1928%)

since

2025/06/30

17.

Millennium Management LLC

(0.1732%)

since

2025/06/30

18.

Integrys Wealth Advisors LLC

(0.167%)

since

2025/06/30

19.

Extended Equity Market Fund K

(0.1608%)

since

2025/06/30

20.

NT Ext Equity Mkt Idx Fd - NL

(0.1588%)

since

2025/06/30

21.

Jane Street Group LLC

(0.1473%)

since

2025/06/30

22.

Marshall Wace Asset Management Ltd

(0.1456%)

since

2025/06/30

23.

Fidelity Total Market Index

(0.1451%)

since

2025/07/31

24.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.1233%)

since

2025/06/30

25.

Spartan Extended Market Index Pool F

(0.118%)

since

2025/07/31

26.

Fidelity Series Total Market Index

(0.1171%)

since

2025/07/31

27.

Tempus Wealth Planning, LLC

(0.1016%)

since

2025/06/30

28.

Northern Trust Extended Eq Market Idx

(0.0987%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - L

(0.0987%)

since

2025/06/30

30.

Virtu Financial LLC

(0.0681%)

since

2025/06/30

31.

Bank of New York Mellon Corp

(0.0623%)

since

2025/06/30

32.

Spartan Total Market Index Pool G

(0.0584%)

since

2025/07/31

33.

T. Rowe Price Associates, Inc.

(0.0516%)

since

2025/06/30

34.

T. Rowe Price U.S. Equities Tr

(0.0516%)

since

2025/06/30

35.

Vanguard Balanced Index Inv

(0.0359%)

since

2025/07/31

36.

Fidelity Nasdaq Composite Index

(0.0326%)

since

2025/07/31

37.

Blackrock US Eq Mkt Fund CF

(0.0286%)

since

2025/07/31

38.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0279%)

since

2025/06/30

39.

Vanguard U.S. Eq Idx £ Acc

(0.0267%)

since

2025/07/31

40.

U.S. Equity Market Fund F

(0.0247%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2067

Latest Release

Date

2025-09-30

EPS Actual

-0.19

EPS Estimate

-0.2133

EPS Difference

0.0233

Surprise Percent

10.9236%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(1)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.